Palisade Bio (PALI) announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D inhibitor being developed for fibrostenotic Crohn’s disease, FSCD, and moderate to severe ulcerative colitis. The Phase 1 program, which included single ascending dose, multiple ascending dose, and cross-over food effect studies in adult healthy volunteers, as well as a small cohort of UC patients, successfully met its primary endpoints of safety, tolerability, and pharmacokinetics. The data support progression into Phase 2 development.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: